Ieq Capital LLC Acquires 41,071 Shares of Accolade, Inc. (NASDAQ:ACCD)

Ieq Capital LLC lifted its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 99.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 82,509 shares of the company's stock after acquiring an additional 41,071 shares during the quarter. Ieq Capital LLC owned 0.10% of Accolade worth $282,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Mission Creek Capital Partners Inc. purchased a new stake in Accolade in the third quarter worth $38,000. Pallas Capital Advisors LLC purchased a new position in Accolade during the fourth quarter valued at $38,000. Wolverine Trading LLC bought a new stake in shares of Accolade during the 3rd quarter valued at $51,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in Accolade by 1,144.1% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company's stock worth $81,000 after purchasing an additional 19,232 shares during the period. Finally, Intech Investment Management LLC bought a new position in Accolade during the 3rd quarter valued at approximately $96,000. Hedge funds and other institutional investors own 84.99% of the company's stock.

Accolade Price Performance

NASDAQ ACCD traded up $0.02 during trading hours on Tuesday, reaching $6.97. The company's stock had a trading volume of 620,082 shares, compared to its average volume of 1,382,341. Accolade, Inc. has a 1 year low of $3.08 and a 1 year high of $10.68. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $571.08 million, a price-to-earnings ratio of -3.10 and a beta of 2.20. The firm's 50-day moving average price is $6.14 and its 200-day moving average price is $4.60.

Remove Ads

Accolade (NASDAQ:ACCD - Get Free Report) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.01. Accolade had a negative return on equity of 20.74% and a negative net margin of 40.36%. On average, equities research analysts predict that Accolade, Inc. will post -1.2 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ACCD shares. Canaccord Genuity Group reiterated a "hold" rating on shares of Accolade in a research note on Wednesday, January 8th. Stephens reaffirmed an "equal weight" rating and issued a $7.03 price objective on shares of Accolade in a report on Wednesday, February 12th. Raymond James reaffirmed a "market perform" rating on shares of Accolade in a report on Thursday, January 9th. Leerink Partners reiterated a "market perform" rating on shares of Accolade in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus restated a "hold" rating and issued a $7.03 price target (down previously from $8.00) on shares of Accolade in a research report on Thursday, January 9th. Twelve equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $6.51.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.